
AbCellera Biologics (NASDAQ:ABCL) is targeting a phase 3 trial of its experimental hot flash treatment around the middle of 2027, as it prepares to release further phase 2 data and discuss the development path with regulators, CEO Carl Hansen said at the UBS Biopharma Conference in London.
The company’s lead drug, ABCL635, is an antibody designed to block NK3R, a target involved in vasomotor symptoms, including hot flashes. AbCellera is developing it as a non-hormonal treatment for symptoms associated with menopause and with hormone-deprivation therapy used in breast and prostate cancer.
Hansen said the phase 3 timing depends on reaching agreement with regulators and preparing manufacturing for the trials. The company is working on options to start with either a prefilled syringe or an auto-injector.
More Phase 2 Data Expected in Early 2027
AbCellera reported four-week phase 2 results in August. Hansen said a single dose produced a reduction of more than 80% in the frequency of moderate-to-severe hot flashes from baseline and about 50% relative to placebo.
Hansen said the placebo-adjusted frequency effect was roughly twice that seen with marketed small-molecule NK3R antagonists, while the effect on severity was four to five times as large. Those figures were comparisons with results for other drugs, not results from a head-to-head trial.
He also said the four-week data showed no signs of elevated liver enzymes or gastrointestinal toxicity. AbCellera’s goal is a once-monthly treatment that avoids the liver-monitoring requirements associated with the oral drugs.
The phase 2 study enrolled 92 women and tested a single 600-milligram dose against placebo. A 12-week update and data from an open-label extension are expected in early 2027.
Hansen cautioned that efficacy is expected to decline after the initial four-week period because participants did not receive another dose during the following eight weeks. The company plans to use that period to assess how the response changes as the antibody washes out and to help determine a phase 3 dose.
In the extension, participants from both the active and placebo groups can receive a 600-milligram dose. Hansen said the company hopes to confirm the initial efficacy findings and maintain the safety profile, including after a repeat dose. He said AbCellera has not released levels of anti-drug antibodies, but has not seen anything that gives it concern.
Commercial Plans and Market Opportunity
Hansen said AbCellera’s initial product plan called for a loading dose followed by a 300-milligram monthly self-administered injection. The company could consider a lower monthly dose or test two doses in phase 3 after reviewing the full data, he said.
The company may also consider a separate study comparing ABCL635 with a physician’s choice of non-hormonal treatments, potentially to support pricing discussions. Hansen said such a study would be alongside, rather than part of, the registrational program. He said AbCellera probably would not compare the drug directly with hormone therapy, which it is not seeking to replace.
Hansen estimated that roughly 12 million women in the United States have moderate-to-severe vasomotor symptoms at any given time, with about 20% unable to tolerate or contraindicated for hormone therapy. Using current net prices for small-molecule treatments, he estimated a potential market of roughly $12 billion for that group before accounting for how many seek treatment.
He said AbCellera is interested in direct-to-consumer and telehealth distribution models and is developing a longer-acting analog, ABCL992, that could offer less frequent dosing and lower manufacturing costs. The company has not decided on a self-pay approach, he added.
AbCellera is not currently seeking a partner for ABCL635 and is focused on taking it into phase 3, Hansen said. The company is considering whether to commercialize it independently, though he said the right partner could help expand its reach.
Hansen also said AbCellera had decided to discontinue another clinical antibody program targeting OX40 ligand despite positive results, citing developments in that drug class.
About AbCellera Biologics (NASDAQ:ABCL)
AbCellera Biologics Inc. is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.
